Axonics' implantable sacral neurostimulator gets European CE mark

May 18, 2021 9:08 AM ETAxonics, Inc. (AXNX)By: Mamta Mayani, SA News Editor
  • Axonics (NASDAQ:AXNX) announces European CE Mark approval of its second generation Axonics r-SNM implantable neurostimulator (INS) and wireless patient remote control with SmartMRI technology.
  • Axonics previously received FDA approval for this INS and remote control during 2020. This version reduces how frequently a patient needs to recharge their sacral neuromodulation device to just once a month for about one hour.
  • The newly approved remote control simplifies the process by which patients can receive a full-body MRI, avoiding the need to visit physician’s office.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.